Insider Cluster (2 insiders) ·Filed Jul 1, 2026

CTNM

Contineum Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago
Insider cluster: 2 insiders, $334K total
Actionable Insight • Neutral

The sales are routine and likely tax/option-exercise related. No bearish signal. Monitor for any upcoming news or earnings, but this cluster alone does not warrant action.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+60d ⚠ clustered
CTNM ▼ -17.28% at T+60d
NEUTRAL call ✗ call lost -17.28% · α vs SPY -20.29% · entry $15.10 → $12.49
Next anchor: T+1d due 3mo ago
Entry anchored
Jul 1, 03:59 PM ET
via exchange tick
T+1d
—
call — · α —
—
due 3mo ago
T+5d
+2.32%
call +2.32% · α +1.39%
$15.45
settled 3mo ago
T+20d
+4.30%
call +4.30% · α +4.72%
$15.75
settled 2mo ago
T+60d
-17.28%
call -17.28% · α -20.29%
$12.49
settled 7d ago

Price Chart

Loading chart...

Executive Summary

CEO Carmine Stengone and CMO Tim Watkins sold small open-market positions on June 30, 2026, totaling $334K (0.05% of market cap). The sales coincide with derivative exercises, suggesting tax- or exercise-cost-related liquidity rather than a bearish signal. Director grants on June 26 are non-cash and routine.

Key Financial Metrics

Direction
selling
Total Value
$334.0K
Insiders
2

Key Facts

  • CEO Stengone sold 10,000 shares at $16.01 ($160K) on June 30, 2026
  • CMO Watkins sold 10,833 shares at $16.02 ($174K) on June 30, 2026
  • Both insiders exercised stock options on the same day, indicating cashless exercise/sale pattern
  • Total open-market sales of $334K represent ~0.05% of CTNM's $613M market cap
  • Seven directors received non-cash grants of 19,000 shares each on June 26, 2026

Financial Impact

Insider sales of $334K are trivial relative to $613M market cap; no material financial impact

insider ownershipdilution

Risk Factors

  • Insider sales could be misinterpreted as bearish by the market
  • Historical CTNM reports have underperformed, suggesting potential overreaction to similar filings

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CTNM-1782947128950
4 reports for CTNM
Performance horizon
Filters
Rows
Reports for CTNM — sortable, filterable
TypeNow
Jul 8, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$15.45 $13.12▼ −15.08%▼ −16.71%$13.12 (−15.08%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$15.10 $12.49▼ −17.28%▼ −20.29%$13.12 (−13.11%)
Jul 1, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$15.10 $12.49▼ −17.28%▼ −20.29%$13.12 (−13.11%)
Mar 5, 2026
30w ago
8-K
NEUTRAL ★ 5/10
$13.88 $13.09▼ −5.69%▼ −18.47%$13.12 (−5.48%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (37h 50m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 1, 2026